In the News

The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.

Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal™

Daisy Petal™ is now commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea

Kerry Love co-founded Sunflower Therapeutics, where she now serves as CEO and president. She shares her journey with BioPharmaReporter.

As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She sits down with BioPharma-Reporter to share her journey.

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.

Recognizing Innovation in Global Life Sciences and Biotechnology HINGHAM, MA, NOVEMBER 19, 2024 ‒ At Sunflower Therapeutics, we’re on a mission to make protein production more accessible, efficient, and cost-effective, and it’s exciting to see our efforts recognized!...

Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.

Grants from the Bill & Melinda Gates Foundation support the optimization of the Dahlia™ small-footprint protein manufacturing system and the de-risking of several protein candidates using Sunflower’s proprietary manufacturing approach.

Sunflower Therapeutics, a public benefit corporation focused on transforming access to biologics medicines for patients worldwide, has delivered its first system for biomanufacturing, the Daisy Petal™ fermentation system.